Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

ves of women with advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each success helps lay the foundation for the next step forward," said William M. Burns, CEO Division Roche Pharmaceuticals. "These results show that we are making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating disease at all stages," he added.

    Presentation of Data

    Herceptin

    Gianni L et al  Neoadjuvant trastuzumab in patients with   Friday 12th,
                    HER2-positive locally advanced breast      December
                    cancer: primary efficacy analysis of the   09:30 hrs
                    NOAH trial                                 General
                                                               Session 3
                                                               (Hall D)

    Xeloda

    Joensuu H et    Significant improvement in                 Sunday 14th,
    al. for The     recurrence-free survival (RFS)             December
    Finnish Breast  when capecitabine (X) is                   11:45 hrs
    Cancer Group    integrated into docetaxel (T)              General
                    5-FU + epirubicin + cyclophosphamide       Session 7
                    (CEF) adjuvant therapy for high-risk
                    early breast cancer (BC): interim
                    analysis of the FinXX-trial.

    Avastin

    Smith IE et al  Primary analysis of study MO19391, an      Saturday
                    open-label safety study of bevacizumab     13th,
                    plus taxane-based therapy as 1st-line      December
                    treatment of patients with locally         07:00 hrs
                    recurrent or metastatic breast cancer.     Poster
                                                               Session 4

'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)...  EndoChoice today announced the launch of its initial ... which will represent 25.6% of its outstanding common stock ... corporation in connection with the offering. The initial ... $15 and $17 per share. The underwriters for the ... up to an additional 937,500 shares of EndoChoice common ...
(Date:5/26/2015)... LONDON , May 26, 2015 ... that technology,s commercial potential ,What,s the future of ... and commercial predictions from 2015. Stay ahead there ... tests, you explore sales results, R&D, opportunities and ... visiongain shows you what,s possible for ...
(Date:5/26/2015)... , May 26, 2015  Array BioPharma ... its Chief Executive Officer, Ron Squarer , ... Conference in New York City. The public is welcome ... on the Array BioPharma website.Event: Jefferies 2015 Global ... 2015Time:1:30 p.m. Eastern Time Webcast: www.arraybiopharma.com  About Array ...
Breaking Medicine Technology:EndoChoice Announces Launch of Its Initial Public Offering 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 3Cell-Based Assays: World Industry and Market Prospects 2015-2025 4Cell-Based Assays: World Industry and Market Prospects 2015-2025 5Cell-Based Assays: World Industry and Market Prospects 2015-2025 6Cell-Based Assays: World Industry and Market Prospects 2015-2025 7
... WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.,(OTCBB: ... that new,data presented at an international influenza ... line outperforms,current cell technologies at replicating human ... step towards the production of,a cell-culture based ...
... of patients receiving highest dose,achieves A1c with ... /PRNewswire-FirstCall/ -- According to,findings presented today at ... Association (ADA) in Chicago, Illinois, the,investigational treatment ... analog under development by Novo Nordisk for ...
Cached Medicine Technology:HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
(Date:5/26/2015)... 2015 National Prevention Week , National ... It is supported by the Substance Abuse and Mental ... awareness of, and action about, substance abuse as well ... coalitions are encouraged to join in promoting prevention strategies, ... issues, and in building community partnerships. , The Voice ...
(Date:5/26/2015)... 2015 i2i Systems, the leader in ... than 15 years, has earned 2014 Patient Centered Medical ... Assurance (NCQA) for its flagship product i2iTracks , ... the work we have done to create healthier populations ... acknowledgement from NCQA once again,” said Janice Nicholson, co-founder ...
(Date:5/26/2015)... New York, NY (PRWEB) May 26, 2015 ... show for a good cause. "The photography show will connect ... difference in their lives.” For the last five years, Raul ... pictures to convey the notion that we are not bounded ... Quechua, a language spoken in Raul’s native country, Bolivia. The ...
(Date:5/26/2015)... 2015 Adenna, Inc ., worldwide ... excited to announce the launch of Enov8 ... made of polyethylene (PE) and approved by the U.S. ... , The Enov8 glove might look like ... mixing salads but our proprietary formula and production technology ...
(Date:5/26/2015)... Viejo, CA (PRWEB) May 26, 2015 ... styles for Final Cut Pro X . ... suspenseful to simple and elegantly styled text. , ... in seconds. , ProTrailer Network can easily complement any ... style desired and within seconds can make professional looking ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 2Health News:i2iTracks Earns NCQA 2014 PCMH Prevalidation 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2Health News:Enov8® Exam Glove by Adenna® Approved by U.S. FDA 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2
... A latest men’s health survey has revealed that men over ... in their 30s or 40s. Their level of satisfaction approximates ... interesting study are published in the February issue of BJU ... 185 Norway men ranged between 20 and 79 years of ...
... Tinnitus is a problem where people are plagued all round their ... from it since she was three. She describes it as the ... a metal spiral staircase. After 25 years later she says that ... an exhibition designer tells that it drives her crazy. Statistics show ...
... UK. The recent reports that many women will be barred from ... caused a lot of commotion among them. // ... 13,000 deaths are expected. But recently the Association of British Insurers ... genetic breast cancer tests. , But it was also ...
... logs, maintained by teenagers from age 13 to 17, ... personal information, //thus making them vulnerable to cyber stalking ... in the technology and social behavior program, will be ... American Association for the Advancement of Science in St. ...
... Immune cells destroy the myelin sheath that surrounds nerve ... myelin is very essential in transmitting the impulses across the ... the metals aluminium and iron in the urine of people ... said that MS could be linked to difficulty in processing ...
... that the euthanasia campaigner Dr Philip Nitschke does not possess ... ,The workshop informs participants of their legal rights about ending ... to be registered as a doctor to carry out his ... denies that he needs a licence. He faces a criminal ...
Cached Medicine News:Health News:50 Plus Men More Satisfied With Sex Life 2Health News:Tinnitus: a problem which is still ambiguous 2Health News:Health insurance in the future would depend on genetic test results 2Health News:Teens need to Exercise Caution While Using Online Blogs 2Health News:Aluminium and Iron Could Play a Vital Role in Multiple Sclerosis 2
... to remove a cast from an arm or ... patients are cut or burned by the cast ... professionals to remove any cast with confidence. This ... cuts and burns from the cast saw and ...
... choice plays an important part in ... particularly where reduced capsule formation, inflammation ... considerations. GORE-TEX Suture, a nonabsorbable, ePTFE ... characteristics sought by a variety of ...
... GORE-TEX ACUSEAL Cardiovascular Patch ... it to "seal" around penetrating ... bleeding by as much as ... with improved suture retention, multi-directional ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
Medicine Products: